Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
British Journal of Haematology|February 6, 2023
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group studyAsma Beldi-Ferchiou, Jean-Philippe Jais, Hervé Ghesquieres, et al.Haematologica|October 3, 2015
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective studyJulien Lazarovici, Peggy Dartigues, Pauline Brice, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association StudyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.Haematologica|May 31, 2022
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baselineCédric Rossi, Marc André, Jehan Dupuis, et al.Haematologica|May 28, 2026
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyJulien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II TrialLuc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.American Journal of Hematology|June 10, 2018
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centersCédric Rossi, Julia Gilhodes, Marie Maerevoet, et al.Blood Advances|October 20, 2023
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Pierre-Julien Viailly, Fanny Drieux, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2017
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneCatherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, et al.American Journal of Hematology|January 6, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 studyJean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, et al.Pageof 5